Pathophysiology of Headaches pp 31-66

Part of the Headache book series (HEAD)

Animal Models of Migraine

Abstract

The headache research field is privileged to have in its preclinical laboratories well-established animal models that significantly facilitate and improve our understanding of headache mechanisms, in particular in terms of the molecular signalling and brain networks involved. A variety of pharmacological screening approaches for novel therapeutics and for the improvement of advanced pharmacological agents can be achieved in translational research utilising these models. The available migraine models have been developed based on our understanding of migraine from clinical, migraine patient-specific evidence. These clinical phenotypes have been successfully employed to model features of the disease physiology in animals and to provide reproducible meaningful physiological measures in the laboratory.

References

  1. 1.
    Headache Classification Committee of the International Headache, S (2013) The international classification of headache disorders, 3rd edn (beta version). Cephalalgia 33:629–808Google Scholar
  2. 2.
    Blau JN (1986) Clinical characteristics of premonitory symptoms in migraine. In: Amery WK, Waquir A (eds) The prelude to the migraine attack. Balliere Tindall, London, pp 39–43Google Scholar
  3. 3.
    Coppola G, Di Lorenzo C, Schoenen J, Pierelli F (2013) Habituation and sensitization in primary headaches. J Headache Pain 14:65PubMedCentralPubMedGoogle Scholar
  4. 4.
    Crawley J et al (2013) Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke. J Thromb Haemost 11:64 (Wiley-Blackwell 111 River St, Hoboken 07030-5774, NJ USA, 2013)Google Scholar
  5. 5.
    Iversen HK, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38:17–24PubMedGoogle Scholar
  6. 6.
    Afridi SK, Kaube H, Goadsby PJ (2004) Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110:675–680PubMedGoogle Scholar
  7. 7.
    Maniyar FH, Sprenger T, Schankin C, Goadsby PJ (2014) The origin of nausea in migraine-A PET study. J Headache Pain 15:84PubMedCentralPubMedGoogle Scholar
  8. 8.
    Pietrobon D (2007) Familial hemiplegic migraine. Neurotherapeutics 4:274–284PubMedGoogle Scholar
  9. 9.
    Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8:e1000412PubMedCentralPubMedGoogle Scholar
  10. 10.
    N.C.R.R.G.W. Group (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Exp Physiol 95:842–844Google Scholar
  11. 11.
    Danos O, Davies K, Lehn P, Mulligan R (2010) The ARRIVE guidelines, a welcome improvement to standards for reporting animal research. J Gene Med 12:559–560PubMedGoogle Scholar
  12. 12.
    Ray BS, Wolff HG (1940) Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 41:813–856Google Scholar
  13. 13.
    Goadsby P, Charbit A, Andreou A, Akerman S, Holland P (2009) Neurobiology of migraine. Neuroscience 161:327–341PubMedGoogle Scholar
  14. 14.
    Akerman S, Holland PR, Goadsby PJ (2011) Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 12:570–584PubMedGoogle Scholar
  15. 15.
    May A et al (1998) Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine. Brain 121(Pt 7):1231–1237PubMedGoogle Scholar
  16. 16.
    Olesen J (1998) Regional cerebral blood flow and oxygen metabolism during migraine with and without aura. Cephalalgia 18:2–4PubMedGoogle Scholar
  17. 17.
    Leão AA (1944) Spreading depression of activity in cerebral cortex. J Neurophysiol 7:359–390Google Scholar
  18. 18.
    Alstadhaug KB (2009) Migraine and the hypothalamus. Cephalalgia 29:809–817PubMedGoogle Scholar
  19. 19.
    Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G (2007) Hypothalamic activation in spontaneous migraine attacks. Headache 47:1418–1426PubMedGoogle Scholar
  20. 20.
    Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137:232–241PubMedGoogle Scholar
  21. 21.
    De Vries P, Villalon CM, Saxena PR (1999) Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur J Pharmacol 375:61–74PubMedGoogle Scholar
  22. 22.
    Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187PubMedGoogle Scholar
  23. 23.
    Schoonman GG et al (2008) Migraine headache is not associated with cerebral or meningeal vasodilatation–a 3T magnetic resonance angiography study. Brain 131:2192–2200PubMedGoogle Scholar
  24. 24.
    Rahmann A et al (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28:226–236PubMedGoogle Scholar
  25. 25.
    Schytz HW et al (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25PubMedGoogle Scholar
  26. 26.
    Bigal ME, Lipton RB (2006) The preventive treatment of migraine. Neurologist 12:204–213PubMedGoogle Scholar
  27. 27.
    Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L (1999) Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 128:1133–1140PubMedCentralPubMedGoogle Scholar
  28. 28.
    Sams A, Jansen-Olesen I (1998) Expression of calcitonin receptor-like receptor and receptor-activity-modifying proteins in human cranial arteries. Neurosci Lett 258:41–44PubMedGoogle Scholar
  29. 29.
    Bigal ME et al (2013) Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia 34:483–492PubMedGoogle Scholar
  30. 30.
    Dodick DW et al (2014) Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 13:1100–1107PubMedGoogle Scholar
  31. 31.
    Reuter U (2014) Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol 13:857–859PubMedGoogle Scholar
  32. 32.
    Heyck H (1969) Pathogenesis of migraine. Res Clin Stud Headache 2:1–28Google Scholar
  33. 33.
    Drummond PD, Lance JW (1984) Facial temperature in migraine, tension-vascular and tension headache. Cephalalgia 4:149–158PubMedGoogle Scholar
  34. 34.
    Guo S et al (2014) Prevalence of right-to-left shunts on transcranial Doppler in chronic migraine and medication-overuse headache. Cephalalgia 34:37–41PubMedGoogle Scholar
  35. 35.
    Den Boer MO et al (1993) On the preservation and regulation of vascular tone in arteriovenous anastomoses during anesthesia. J Appl Physiol 75:782–789Google Scholar
  36. 36.
    Villalon CM et al (1999) Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors. Br J Pharmacol 126:585–594PubMedCentralPubMedGoogle Scholar
  37. 37.
    Kapoor K et al (2004) Assessment of anti-migraine potential of a novel alpha-adrenoceptor agonist S19014: effects on porcine carotid and regional haemodynamics and human coronary artery. Cephalalgia 24:425–438PubMedGoogle Scholar
  38. 38.
    Verheggen R, Hundeshagen AG, Brown AM, Schindler M, Kaumann AJ (1998) 5-HT1B receptor-mediated contractions in human temporal artery: evidence from selective antagonists and 5-HT receptor mRNA expression. Br J Pharmacol 124:1345–1354PubMedCentralPubMedGoogle Scholar
  39. 39.
    Muller-Schweinitzer E, Weidmann H (1977) Regional differences in the responsiveness of isolated arteries from cattle, dog and man. Agents Actions 7:383–389PubMedGoogle Scholar
  40. 40.
    Franco-Cereceda A, Rudehill A, Lundberg JM (1987) Calcitonin gene-related peptide but not substance P mimics capsaicin-induced coronary vasodilation in the pig. Eur J Pharmacol 142:235–243PubMedGoogle Scholar
  41. 41.
    Petersen KA, Nilsson E, Olesen J, Edvinsson L (2005) Presence and function of the calcitonin gene-related peptide receptor on rat pial arteries investigated in vitro and in vivo. Cephalalgia 25:424–432PubMedGoogle Scholar
  42. 42.
    Faraci FM, Breese KR (1994) Dilatation of cerebral arterioles in response to N-methyl-D-aspartate: role of CGRP and acetylcholine. Brain Res 640:93–97PubMedGoogle Scholar
  43. 43.
    Busija DW, Chen J (1992) Effects of trigeminal neurotransmitters on piglet pial arterioles. J Dev Physiol 18:67–72PubMedGoogle Scholar
  44. 44.
    Gupta S et al (2006) Intravital microscopy on a closed cranial window in mice: a model to study trigeminovascular mechanisms involved in migraine. Cephalalgia 26:1294–1303PubMedGoogle Scholar
  45. 45.
    Akerman S, Williamson DJ, Kaube H, Goadsby PJ (2002) The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 452:223–228PubMedGoogle Scholar
  46. 46.
    Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia 17:518–524PubMedGoogle Scholar
  47. 47.
    Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J (2004) Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 143:697–704PubMedCentralPubMedGoogle Scholar
  48. 48.
    Gupta S, Villalon CM (2010) The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors. Pharmacol Ther 128:170–190PubMedGoogle Scholar
  49. 49.
    Gupta S, Bhatt DK, Boni LJ, Olesen J (2010) Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia 30:27–36PubMedGoogle Scholar
  50. 50.
    Tvedskov JF et al (2005) No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58:561–568PubMedGoogle Scholar
  51. 51.
    Edvinsson L, Goadsby PJ (1994) Neuropeptides in migraine and cluster headache. Cephalalgia 14:320–327PubMedGoogle Scholar
  52. 52.
    Messlinger K, Hotta H, Pawlak M, Schmidt RF (1997) Effects of the 5-HT1 receptor agonists, sumatriptan and CP 93,129, on dural arterial flow in the rat. Eur J Pharmacol 332:173–181PubMedGoogle Scholar
  53. 53.
    Kurosawa M, Messlinger K, Pawlak M, Schmidt RF (1995) Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 114:1397–1402PubMedCentralPubMedGoogle Scholar
  54. 54.
    Geppetti P, Rossi E, Chiarugi A, Benemei S (2012) Antidromic vasodilatation and the migraine mechanism. J Headache Pain 13:103–111PubMedCentralPubMedGoogle Scholar
  55. 55.
    Levy D, Burstein R, Strassman AM (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698–705PubMedGoogle Scholar
  56. 56.
    Akerman S, Williamson DJ, Hill RG, Goadsby PJ (2001) The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 424:53–58PubMedGoogle Scholar
  57. 57.
    Escott KJ, Connor HE, Brain SD, Beattie DT (1995) The involvement of calcitonin gene-related peptide (CGRP) and substance P in feline pial artery diameter responses evoked by capsaicin. Neuropeptides 29:129–135PubMedGoogle Scholar
  58. 58.
    Nagy I, Friston D, Valente JS, Torres Perez JV, Andreou AP (2014) Pharmacology of the capsaicin receptor, transient receptor potential vanilloid type-1 ion channel. Prog Drug Res Fortschritte der Arzneimittelforschung Progres des recherches pharmaceutiques 68:39–76Google Scholar
  59. 59.
    Summ O, Akerman S, Holland PR, Goadsby PJ (2009) The TRPV1 receptor antagonist, A-993610, shows no effect on neurogenic dural dilation but is able to block capsaicin induced dilation. Cephalalgia 29:136Google Scholar
  60. 60.
    Neeb L, Reuter U (2007) Nitric oxide in migraine. CNS Neurol Disord Drug Targets 6:258–264PubMedGoogle Scholar
  61. 61.
    Bellamy J, Bowen EJ, Russo AF, Durham PL (2006) Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur J Neurosci 23:2057–2066PubMedCentralPubMedGoogle Scholar
  62. 62.
    Li J, Vause CV, Durham PL (2008) Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res 1196:22–32PubMedCentralPubMedGoogle Scholar
  63. 63.
    Messlinger K, Suzuki A, Pawlak M, Zehnter A, Schmidt RF (2000) Involvement of nitric oxide in the modulation of dural arterial blood flow in the rat. Br J Pharmacol 129:1397–1404PubMedCentralPubMedGoogle Scholar
  64. 64.
    Olesen J et al (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110PubMedGoogle Scholar
  65. 65.
    Ho TW et al (2009) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115–2123Google Scholar
  66. 66.
    Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat–intravital microscope studies. Cephalalgia 17:525–531PubMedGoogle Scholar
  67. 67.
    Akerman S, Goadsby PJ (2005) Topiramate inhibits trigeminovascular activation: an intravital microscopy study. Br J Pharmacol 146:7–14PubMedCentralPubMedGoogle Scholar
  68. 68.
    Williamson DJ, Hargreaves RJ (2001) Neurogenic inflammation in the context of migraine. Microsc Res Tech 53:167–178PubMedGoogle Scholar
  69. 69.
    Carmody J, Pawlak M, Messlinger K (1996) Lack of a role for substance P in the control of dural arterial flow. Exp Brain Res 111:424–428PubMedGoogle Scholar
  70. 70.
    Goldstein DJ et al (2001) Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 21:102–106PubMedGoogle Scholar
  71. 71.
    Goldstein DJ et al (1997) Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 17:785–790PubMedGoogle Scholar
  72. 72.
    Akerman S, Holland PR, Lasalandra MP, Goadsby PJ (2010) Inhibition of trigeminovascular dural nociceptive afferents by Ca(2+)-activated K(+) (MaxiK/BK(Ca)) channel opening. Pain 151:128–136PubMedGoogle Scholar
  73. 73.
    Akerman S, Holland PR, Goadsby PJ (2007) Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. J Pharmacol Exp Ther 320:64–71PubMedGoogle Scholar
  74. 74.
    Holland PR, Akerman S, Goadsby PJ (2005) Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 315:1380–1385PubMedGoogle Scholar
  75. 75.
    Shepheard S et al (1999) Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia 19:851–858PubMedGoogle Scholar
  76. 76.
    Summ O, Andreou AP, Akerman S, Goadsby PJ (2010) A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. J Headache Pain 11:477–483PubMedCentralPubMedGoogle Scholar
  77. 77.
    Akerman S, Williamson DJ, Goadsby PJ (2003) Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism. Br J Pharmacol 140:558–566PubMedCentralPubMedGoogle Scholar
  78. 78.
    Gupta S et al (2007) Female sex hormones and rat dural vasodilatation to CGRP, periarterial electrical stimulation and capsaicin. Headache 47:225–235PubMedGoogle Scholar
  79. 79.
    Akerman S, Goadsby PJ (2005) The role of dopamine in a model of trigeminovascular nociception. J Pharmacol Exp Ther 314:162–169PubMedGoogle Scholar
  80. 80.
    Andreou AP, Holland PR, Goadsby PJ (2009) Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation. Br J Pharmacol 157:464–473PubMedCentralPubMedGoogle Scholar
  81. 81.
    Markowitz S, Saito K, Moskowitz MA (1988) Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8:83–91PubMedGoogle Scholar
  82. 82.
    Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43:S16–S20PubMedGoogle Scholar
  83. 83.
    Andreou AP, Summ O, Charbit AR, Romero-Reyes M, Goadsby PJ (2010) Animal models of headache: from bedside to bench and back to bedside. Expert Rev Neurother 10:389–411PubMedGoogle Scholar
  84. 84.
    Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA (1992) Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48:187–203PubMedGoogle Scholar
  85. 85.
    Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. Annu Rev Physiol 75:365–391PubMedGoogle Scholar
  86. 86.
    Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129–4136PubMedGoogle Scholar
  87. 87.
    Strassman AM, Raymond SA, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384:560–564PubMedGoogle Scholar
  88. 88.
    Kandere-Grzybowska K et al (2003) Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. Brain Res 980:213–220PubMedGoogle Scholar
  89. 89.
    Goadsby PJ, Edvinsson L (1998) Neuropeptides in headache. Eur J Neurol 5:329–341Google Scholar
  90. 90.
    Delepine L, Aubineau P (1997) Plasma protein extravasation induced in the rat dura mater by stimulation of the parasympathetic sphenopalatine ganglion. Exp Neurol 147:389–400PubMedGoogle Scholar
  91. 91.
    Buzzi MG, Sakas DE, Moskowitz MA (1989) Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 165:251–258PubMedGoogle Scholar
  92. 92.
    Schuh-Hofer S, Tayefeh M, Reuter U, Dirnagl U, Arnold G (2006) Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. Headache 46:276–285PubMedGoogle Scholar
  93. 93.
    Phebus LA et al (1997) Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 61:2117–2126PubMedGoogle Scholar
  94. 94.
    Yu XJ, Cutrer FM, Moskowitz MA, Waeber C (1997) The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology 36:83–91PubMedGoogle Scholar
  95. 95.
    Cutrer FM, Yu XJ, Ayata G, Moskowitz MA, Waeber C (1999) Effects of PNU-109,291, a selective 5-HT1D receptor agonist, on electrically induced dural plasma extravasation and capsaicin-evoked c-fos immunoreactivity within trigeminal nucleus caudalis. Neuropharmacology 38:1043–1053PubMedGoogle Scholar
  96. 96.
    Buzzi MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206PubMedCentralPubMedGoogle Scholar
  97. 97.
    Polley JS et al (1997) The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system. Regul Pept 68:23–29PubMedGoogle Scholar
  98. 98.
    Phebus LA et al (1997) The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs. Life Sci 60:1553–1561PubMedGoogle Scholar
  99. 99.
    Goldstein DJ, Offen WW, Klein EG, Phebus LA (1999) Lanepitant an NK-1 antagonist in migraine prophylaxis. Cephalalgia 19:377Google Scholar
  100. 100.
    Peroutka SJ (2005) Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 5:304–311PubMedGoogle Scholar
  101. 101.
    Kruuse C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126:241–247PubMedGoogle Scholar
  102. 102.
    Goadsby PJ (2007) Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13:39–44PubMedGoogle Scholar
  103. 103.
    Afridi SK, Goadsby PJ (2006) Neuroimaging of migraine. Curr Pain Headache Rep 10:221–224PubMedGoogle Scholar
  104. 104.
    Wolff HG (1948) Headache and other head pain. Oxford University Press, New YorkGoogle Scholar
  105. 105.
    Penfield W (1934) A contribution to the mechanism of intracranial pain. In: Proceedings of the association for research in nervous and mental disease, pp 399–415Google Scholar
  106. 106.
    Penfield W, McNaughton F (1940) Dural headache and innervation of the dura matter. Arch Neurol Psychiatry 44:43–75Google Scholar
  107. 107.
    White JP, Cibelli M, Fidalgo AR, Nagy I (2011) Extracellular signal-regulated kinases in pain of peripheral origin. Eur J Pharmacol 650:8–17PubMedGoogle Scholar
  108. 108.
    Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ (1993) Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 629:95–102PubMedGoogle Scholar
  109. 109.
    Burstein R, Yamamura H, Malick A, Strassman AM (1998) Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol 79:964–982PubMedGoogle Scholar
  110. 110.
    Hoskin KL, Bulmer DC, Goadsby PJ (1999) Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett 266:173–176PubMedGoogle Scholar
  111. 111.
    Hunt SP, Pini A, Evan G (1987) Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 328:632–634PubMedGoogle Scholar
  112. 112.
    Keay KA, Bandler R (1998) Vascular head pain selectively activates ventrolateral periaqueductal gray in the cat. Neurosci Lett 245:58–60PubMedGoogle Scholar
  113. 113.
    Malick A, Jakubowski M, Elmquist JK, Saper CB, Burstein R (2001) A neurohistochemical blueprint for pain-induced loss of appetite. Proc Natl Acad Sci U S A 98:9930–9935PubMedCentralPubMedGoogle Scholar
  114. 114.
    Pearse DD, Bushell G, Leah JD (2001) Jun, Fos and Krox in the thalamus after C-fiber stimulation: coincident-input-dependent expression, expression across somatotopic boundaries, and nucleolar translocation. Neuroscience 107:143–159PubMedGoogle Scholar
  115. 115.
    Knyihar-Csillik E et al (2007) Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. Neurosci Lett 418:122–126PubMedGoogle Scholar
  116. 116.
    Hoskin KL, Goadsby PJ (1998) Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 150:45–51PubMedGoogle Scholar
  117. 117.
    Maneepak M, le Grand S, Srikiatkhachorn A (2009) Serotonin depletion increases nociception-evoked trigeminal NMDA receptor phosphorylation. Headache 49:375–382PubMedGoogle Scholar
  118. 118.
    Tanuri FC et al (2009) Melatonin treatment decreases c-fos expression in a headache model induced by capsaicin. J Headache Pain 10:105–110PubMedCentralPubMedGoogle Scholar
  119. 119.
    Cutrer FM, Limmroth V, Ayata G, Moskowitz MA (1995) Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 116:3199–3204PubMedCentralPubMedGoogle Scholar
  120. 120.
    Sixt ML, Messlinger K, Fischer MJ (2009) Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 132:3134–3141PubMedGoogle Scholar
  121. 121.
    Goadsby PJ, Hoskin KL (1999) Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 82:15–22PubMedGoogle Scholar
  122. 122.
    Goadsby PJ, Hoskin KL, Knight YE (1998) Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 86:337–343PubMedGoogle Scholar
  123. 123.
    Edling Y, Ingelman-Sundberg M, Simi A (2007) Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. Glia 55:328–340PubMedGoogle Scholar
  124. 124.
    Dragunow M, Faull RL (1990) MK801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neurosci Lett 113:144–150PubMedGoogle Scholar
  125. 125.
    Flores C, Arvanitogiannis A, Shizgal P (1997) Fos-like immunoreactivity in forebrain regions following self-stimulation of the lateral hypothalamus and the ventral tegmental area. Behav Brain Res 87:239–251PubMedGoogle Scholar
  126. 126.
    Lima D, Avelino A (1994) Spinal c-fos expression is differentially induced by brief or persistent noxious stimulation. Neuroreport 5:1853–1856PubMedGoogle Scholar
  127. 127.
    Goadsby PJ, Zagami AS (1991) Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 114(Pt 2):1001–1011PubMedGoogle Scholar
  128. 128.
    Lambert GA, Goadsby PJ, Zagami AS, Duckworth JW (1988) Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat. Brain Res 453:143–149PubMedGoogle Scholar
  129. 129.
    Olesen J et al (1990) Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 28:791–798PubMedGoogle Scholar
  130. 130.
    Escott KJ, Beattie DT, Connor HE, Brain SD (1995) Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide. Brain Res 669:93–99PubMedGoogle Scholar
  131. 131.
    Oshinsky ML, Luo J (2006) Neurochemistry of trigeminal activation in an animal model of migraine. Headache 46(Suppl 1):S39–S44PubMedGoogle Scholar
  132. 132.
    Goadsby PJ, Edvinsson L (1993) The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 33:48–56PubMedGoogle Scholar
  133. 133.
    Diener HC et al (1991) Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs. J Neurol 238:245–250PubMedGoogle Scholar
  134. 134.
    Hoskin KL, Kaube H, Goadsby PJ (1996) Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain 119(Pt 1):249–256PubMedGoogle Scholar
  135. 135.
    Davis KD, Dostrovsky JO (1986) Activation of trigeminal brain-stem nociceptive neurons by dural artery stimulation. Pain 25:395–401PubMedGoogle Scholar
  136. 136.
    Strassman A, Mason P, Moskowitz M, Maciewicz R (1986) Response of brainstem trigeminal neurons to electrical stimulation of the dura. Brain Res 379:242–250PubMedGoogle Scholar
  137. 137.
    Bolton S, O’Shaughnessy CT, Goadsby PJ (2005) Properties of neurons in the trigeminal nucleus caudalis responding to noxious dural and facial stimulation. Brain Res 1046:122–129PubMedGoogle Scholar
  138. 138.
    Bartsch T, Goadsby PJ (2003) Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 126:1801–1813PubMedGoogle Scholar
  139. 139.
    Xiao Y, Richter JA, Hurley JH (2008) Release of glutamate and CGRP from trigeminal ganglion neurons: role of calcium channels and 5-HT1 receptor signaling. Mol Pain 4:12PubMedCentralPubMedGoogle Scholar
  140. 140.
    Shields KG, Goadsby PJ (2005) Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 128:86–97PubMedGoogle Scholar
  141. 141.
    Shields KG, Goadsby PJ (2006) Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 23:491–501PubMedGoogle Scholar
  142. 142.
    Lambert GA et al (2014) Stimulation of dural vessels excites the SI somatosensory cortex of the cat via a relay in the thalamus. Cephalalgia 34:243–257PubMedGoogle Scholar
  143. 143.
    Cumberbatch MJ, Hill RG, Hargreaves RJ (1998) Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia 18:659–663PubMedGoogle Scholar
  144. 144.
    Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ (1999) Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol 126:1478–1486PubMedCentralPubMedGoogle Scholar
  145. 145.
    Fischer MJ, Koulchitsky S, Messlinger K (2005) The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J Neurosci 25:5877–5883PubMedGoogle Scholar
  146. 146.
    Andreou A, Goadsby P (2010) Topiramate acts on kainate receptors within the trigeminothalamic pathway. Headache 50:S5 (Wiley-Blackwell Publishing, Inc Commerce Place, 350 Main St, Malden 02148, MA USA, 2010)Google Scholar
  147. 147.
    Andreou AP, Goadsby PJ (2009) Therapeutic potential of novel glutamate receptor antagonists in migraine. Expert Opin Investig Drugs 18:789–803PubMedGoogle Scholar
  148. 148.
    Storer RJ, Goadsby PJ (2009) N-Methyl-d-Aspartate receptor channel complex blockers including memantine and magnesium inhibit nociceptive traffic in the trigeminocervical complex of the rat. Cephalalgia 29:135Google Scholar
  149. 149.
    Andreou A, Goadsby P (2009) LY466195, a clinically active compound in the acute treatment of migraine, inhibits activation in the trigeminocervical complex and the ventroposteromedial thalamus after nociceptive trigeminovascular activation. Cephalalgia 29:132 (Wiley-Blackwell Publishing, Inc Commerce Place, 350 Main St, Malden 02148, MA USA, 2009)Google Scholar
  150. 150.
    Andreou A, Goadsby P, Holland P (2007) Pre- and post-synaptic involvement of GluR5 kainate receptors in trigeminovascular nociceptive processing. Cephalalgia 27:605Google Scholar
  151. 151.
    Andreou A, Holland P, Goadsby P (2008) iGluR5 kainate receptors modulate trigeminovascular nociceptive transmission in thalamic ventroposteromedial nucleus. Headache 48:S5–S6 (Blackwell Publishing 9600 GARSINGTON RD, Oxford OX4 2DQ, Oxon, England, 2008)Google Scholar
  152. 152.
    Andreou A, Storer R, Holland P, Goadsby P (2006) CNQX inhibits trigeminovascular neurons in the rat: a microiontophoresis study. Cephalalgia 26:1383 (Blackwell Publishing 9600 GARSINGTON RD, Oxford OX4 2DQ, Oxon, England, 2006)Google Scholar
  153. 153.
    Andreou AP, Goadsby PJ (2011) Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 31:1343–1358PubMedGoogle Scholar
  154. 154.
    Hoffmann J et al (2014) Evidence for orexinergic mechanisms in migraine. Neurobiol Dis 74C:137–143Google Scholar
  155. 155.
    Charbit A, Akerman S, Goadsby P (2009) Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex. J Pharmacol Exp Ther 331(2):752–763PubMedGoogle Scholar
  156. 156.
    Lambert GA et al (2009) The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch Pharmacol 380:311–325PubMedGoogle Scholar
  157. 157.
    Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS (1992) The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 597:321–330PubMedGoogle Scholar
  158. 158.
    Storer RJ, Goadsby PJ (1997) Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 120(Pt 12):2171–2177PubMedGoogle Scholar
  159. 159.
    Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine–current understanding and treatment. N Engl J Med 346:257–270PubMedGoogle Scholar
  160. 160.
    Storer RJ, Akerman S, Goadsby PJ (2004) Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 142:1171–1181PubMedCentralPubMedGoogle Scholar
  161. 161.
    Summ O, Charbit AR, Andreou AP, Goadsby PJ (2010) Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133:2540–2548PubMedGoogle Scholar
  162. 162.
    Andreou AP, Shields KG, Goadsby PJ (2010) GABA and valproate modulate trigeminovascular nociceptive transmission in the thalamus. Neurobiol Dis 37:314–323PubMedGoogle Scholar
  163. 163.
    Bartsch T, Goadsby PJ (2002) Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125:1496–1509PubMedGoogle Scholar
  164. 164.
    Bartsch T, Paemeleire K, Goadsby PJ (2009) Neurostimulation approaches to primary headache disorders. Curr Opin Neurol 22:262–268PubMedGoogle Scholar
  165. 165.
    Weiller C et al (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658–660PubMedGoogle Scholar
  166. 166.
    Knight YE, Bartsch T, Kaube H, Goadsby PJ (2002) P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 22:RC213PubMedGoogle Scholar
  167. 167.
    Goadsby PJ, Lambert GA, Lance JW (1982) Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Res 249:247–254PubMedGoogle Scholar
  168. 168.
    Supronsinchai W et al (2013) GABAA receptors in the nucleus raphe magnus modulate firing of neurons in the trigeminocervical complex. J Headache Pain 14:P67PubMedCentralGoogle Scholar
  169. 169.
    Charbit AR, Akerman S, Holland PR, Goadsby PJ (2009) Neurons of the dopaminergic/calcitonin gene-related peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J Neurosci 29:12532–12541PubMedGoogle Scholar
  170. 170.
    Robert C et al (2013) Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci 33:8827–8840PubMedGoogle Scholar
  171. 171.
    Noseda R, Kainz V, Borsook D, Burstein R (2014) Neurochemical pathways that converge on thalamic trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, stress and anxiety. PLoS One 9:e103929PubMedCentralPubMedGoogle Scholar
  172. 172.
    Noseda R et al (2010) A neural mechanism for exacerbation of headache by light. Nat Neurosci 13:239–245PubMedCentralPubMedGoogle Scholar
  173. 173.
    Burstein R, Cutrer MF, Yarnitsky D (2000) The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123(Pt 8):1703–1709PubMedGoogle Scholar
  174. 174.
    Burstein R, Jakubowski M (2004) Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 55:27–36PubMedGoogle Scholar
  175. 175.
    Pozo-Rosich P, Oshinsky M (2005) Dihydroergotamine (DHE) reverses central sensitization in the trigeminal nucleus caudalis. Headache 45:767Google Scholar
  176. 176.
    Jakubowski M et al (2005) Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 45:850–861PubMedGoogle Scholar
  177. 177.
    Levy D, Zhang XC, Jakubowski M, Burstein R (2008) Sensitization of meningeal nociceptors: inhibition by naproxen. Eur J Neurosci 27:917–922PubMedCentralPubMedGoogle Scholar
  178. 178.
    Burstein R et al (2010) Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68:81–91PubMedCentralPubMedGoogle Scholar
  179. 179.
    Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1:73–80PubMedGoogle Scholar
  180. 180.
    Tvedskov JF, Iversen HK, Olesen J, Tfelt-Hansen P (2010) Nitroglycerin provocation in normal subjects is not a useful human migraine model? Cephalalgia 30:928–932PubMedGoogle Scholar
  181. 181.
    Thomsen LL, Brennum J, Iversen HK, Olesen J (1996) Effect of a nitric oxide donor (glyceryl trinitrate) on nociceptive thresholds in man. Cephalalgia 16:169–174PubMedGoogle Scholar
  182. 182.
    Culotta E, Koshland DE (1992) No news is good-news. Science 258:1862–1865PubMedGoogle Scholar
  183. 183.
    Tassorelli C, Greco R, Cappelletti D, Sandrini G, Nappi G (2005) Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and L-arginine. Brain Res 1051:17–24PubMedGoogle Scholar
  184. 184.
    Olesen J, Jansen-Olesen I (2012) Towards a reliable animal model of migraine. Cephalalgia 32:578–580PubMedGoogle Scholar
  185. 185.
    Ramachandran R et al (2012) A naturalistic glyceryl trinitrate infusion migraine model in the rat. Cephalalgia 32:73–84PubMedGoogle Scholar
  186. 186.
    Tassorelli C, Joseph SA (1996) Systemic nitroglycerin activates peptidergic and catecholaminergic pathways in rat brain. Peptides 17:443–449PubMedGoogle Scholar
  187. 187.
    Greco R et al (2013) Effect of sex and estrogens on neuronal activation in an animal model of migraine. Headache 53:288–296PubMedGoogle Scholar
  188. 188.
    Dieterle A, Fischer MJ, Link AS, Neuhuber WL, Messlinger K (2011) Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia 31:31–42PubMedGoogle Scholar
  189. 189.
    Ramachandran R et al (2014) Nitric oxide synthase, calcitonin gene-related peptide and NK-1 receptor mechanisms are involved in GTN-induced neuronal activation. Cephalalgia 34:136–147PubMedGoogle Scholar
  190. 190.
    Kruuse C, Iversen HK, Jansen-Olesen I, Edvinsson L, Olesen J (2010) Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia 30:467–474PubMedGoogle Scholar
  191. 191.
    Offenhauser N et al (2005) CGRP release and c-fos expression within trigeminal nucleus caudalis of the rat following glyceryltrinitrate infusion. Cephalalgia 25:225–236PubMedGoogle Scholar
  192. 192.
    Bates E et al (2009) Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30(2):170–178Google Scholar
  193. 193.
    Greco R et al (2013) Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia 34:594–604PubMedGoogle Scholar
  194. 194.
    Akerman S, Goadsby PJ (2014) Acute anti-migraine treatments abort established central sensitization of trigeminovascular neurons: validation of a novel translational approach. Headache 54:2–3Google Scholar
  195. 195.
    Andreou AP, Chamberlain J (2014) Nitric oxide alters the neuronal firing of the dopaminergic hypothalamic nucleus A11. Headache 54:6–7Google Scholar
  196. 196.
    Greco R et al (2008) Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. Brain Res 1238:215–223PubMedGoogle Scholar
  197. 197.
    Rasmussen BK, Olesen J (1992) Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12:221–228PubMedGoogle Scholar
  198. 198.
    Leao AAP (1944) Spreading depression of activity in cerebral cortex. J Neurophysiol 7:359–390Google Scholar
  199. 199.
    Olesen J (1991) Cerebral and extracranial circulatory disturbances in migraine: pathophysiological implications. Cerebrovasc Brain Metab Rev 3:1–28PubMedGoogle Scholar
  200. 200.
    Brennan KC et al (2007) Distinct vascular conduction with cortical spreading depression. J Neurophysiol 97:4143–4151PubMedGoogle Scholar
  201. 201.
    Haghir H, Kovac S, Speckmann EJ, Zilles K, Gorji A (2009) Patterns of neurotransmitter receptor distributions following cortical spreading depression. Neuroscience 163(4):1340–1352PubMedGoogle Scholar
  202. 202.
    Gorji A et al (2001) Spreading depression in human neocortical slices. Brain Res 906:74–83PubMedGoogle Scholar
  203. 203.
    Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC (2000) Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55:139–141PubMedGoogle Scholar
  204. 204.
    Vinogradova LV, Kuznetsova GD, Coenen AM (2009) Unilateral cortical spreading depression induced by sound in rats. Brain Res 1286:201–207PubMedGoogle Scholar
  205. 205.
    Bolay H, Akcali D, Yalcinkaya D, Sara Y (2009) Behavioral changes associated with cortical spreading depression in awake rats. Cephalalgia 29:142Google Scholar
  206. 206.
    Akcali D, Sayin A, Sara Y, Bolay H (2010) Does single cortical spreading depression elicit pain behaviour in freely moving rats? Cephalalgia 30:1195–1206PubMedGoogle Scholar
  207. 207.
    Fioravanti B et al (2011) Evaluation of cutaneous allodynia following induction of cortical spreading depression in freely moving rats. Cephalalgia 31:1090–1100PubMedCentralPubMedGoogle Scholar
  208. 208.
    Ayata C (2009) Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 29:1095–1114PubMedGoogle Scholar
  209. 209.
    Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59:652–661PubMedGoogle Scholar
  210. 210.
    Bogdanov VB et al (2011) Migraine preventive drugs differentially affect cortical spreading depression in rat. Neurobiol Dis 41:430–435PubMedGoogle Scholar
  211. 211.
    Andreou A et al (2010) Acid-sensing ion channel 1-A potential site of action of amiloride in migraine with aura. J Headache Pain 11:S125 (Springer-Verlag ITALIA SRL VIA DECEMBRIO, 28, Milan, 20137, Italy, 2010)Google Scholar
  212. 212.
    Holland PR et al (2012) Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol 72:559–563PubMedGoogle Scholar
  213. 213.
    Holland PR, Schembri C, Fredrick J, Goadsby PJ (2009) Transcranial magnetic stimulation for the treatment of migraine aura? Cephalalgia 29:22PubMedGoogle Scholar
  214. 214.
    Andreou AP, Summ O, Schembri CT, Fredrick JP, Goadsby PJ (2010) Transcranial magnetic stimulation inhibits cortical spreading depression but not trigeminocervical activation in animal models of migraine. Headache 50:S58Google Scholar
  215. 215.
    Ingvardsen BK, Laursen H, Olsen UB, Hansen AJ (1997) Possible mechanism of c-fos expression in trigeminal nucleus caudalis following cortical spreading depression. Pain 72:407–415PubMedGoogle Scholar
  216. 216.
    Supornsilpchai W, Sanguanrangsirikul S, Maneesri S, Srikiatkhachorn A (2006) Serotonin depletion, cortical spreading depression, and trigeminal nociception. Headache 46:34–39PubMedGoogle Scholar
  217. 217.
    Moskowitz MA, Nozaki K, Kraig RP (1993) Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 13:1167–1177PubMedCentralPubMedGoogle Scholar
  218. 218.
    Herrera DG, Robertson HA (1996) Activation of c-fos in the brain. Prog Neurobiol 50:83–107PubMedGoogle Scholar
  219. 219.
    Ebersberger A, Schaible HG, Averbeck B, Richter F (2001) Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol 49:7–13PubMedGoogle Scholar
  220. 220.
    Bolay H et al (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142PubMedGoogle Scholar
  221. 221.
    Zhang X et al (2011) Activation of central trigeminovascular neurons by cortical spreading depression. Ann Neurol 69:855–865PubMedCentralPubMedGoogle Scholar
  222. 222.
    Karatas H et al (2013) Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339:1092–1095PubMedGoogle Scholar
  223. 223.
    Read SJ, Hirst WD, Upton N, Parsons AA (2001) Cortical spreading depression produces increased cGMP levels in cortex and brain stem that is inhibited by tonabersat (SB-220453) but not sumatriptan. Brain Res 891:69–77PubMedGoogle Scholar
  224. 224.
    Goadsby PJ, Ferrari MD, Csanyi A, Olesen J, Mills JG (2009) Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 29(7):742–750PubMedGoogle Scholar
  225. 225.
    Noseda R, Constandil L, Bourgeais L, Chalus M, Villanueva L (2010) Changes of meningeal excitability mediated by corticotrigeminal networks: a link for the endogenous modulation of migraine pain. J Neurosci 30:14420–14429PubMedGoogle Scholar
  226. 226.
    Lambert GA, Hoskin KL, Zagami AS (2008) Cortico-NRM influences on trigeminal neuronal sensation. Cephalalgia 28:640–652PubMedGoogle Scholar
  227. 227.
    Lambert GA, Michalicek J, Storer RJ, Zagami AS (1999) Effect of cortical spreading depression on activity of trigeminovascular sensory neurons. Cephalalgia 19:631–638PubMedGoogle Scholar
  228. 228.
    Andreou AP, Sprenger T, Goadsby PJ (2012) Cortical spreading depression-evoked discharges on trigeminothalamic neurons. Headache 52:900Google Scholar
  229. 229.
    Andreou AP, Sprenger T, Goadsby PJ (2013) Cortical modulation of thalamic function during cortical spreading depression- unraveling a new central mechanism involved in migraine aura. J Headache Pain 14:16Google Scholar
  230. 230.
    van den Maagdenberg AM, Haan J, Terwindt GM, Ferrari MD (2007) Migraine: gene mutations and functional consequences. Curr Opin Neurol 20:299–305PubMedGoogle Scholar
  231. 231.
    Leo L et al (2011) Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. PLoS Genet 7:e1002129PubMedCentralPubMedGoogle Scholar
  232. 232.
    Eikermann-Haerter K et al (2009) Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest 119:99–109PubMedCentralPubMedGoogle Scholar
  233. 233.
    Tottene A et al (2009) Enhanced excitatory transmission at cortical synapses as the basis for facilitated spreading depression in Ca(v)2.1 knockin migraine mice. Neuron 61:762–773PubMedGoogle Scholar
  234. 234.
    Langford DJ et al (2010) Coding of facial expressions of pain in the laboratory mouse. Nat Methods 7:447–449PubMedGoogle Scholar
  235. 235.
    Chanda ML et al (2013) Behavioral evidence for photophobia and stress-related ipsilateral head pain in transgenic Cacna1a mutant mice. Pain 154:1254–1262PubMedGoogle Scholar
  236. 236.
    Mathew R et al (2011) Immunohistochemical characterization of calcitonin gene-related peptide in the trigeminal system of the familial hemiplegic migraine 1 knock-in mouse. Cephalalgia 31:1368–1380PubMedGoogle Scholar
  237. 237.
    Hansen JM et al (2008) Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia 28:367–375PubMedGoogle Scholar
  238. 238.
    Hansen JM, Thomsen LL, Olesen J, Ashina M (2008) Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 71:841–847PubMedGoogle Scholar
  239. 239.
    Park J et al (2014) Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: a Fos protein study. Neurobiol Dis 64:1–7PubMedGoogle Scholar
  240. 240.
    Moon H-S et al (2010) Altered responses in the descending modulatory system of transgenic mice with the CACNA1A mutation. Headache 50:67Google Scholar
  241. 241.
    Xu Y et al (2005) Functional consequences of a CKIdelta mutation causing familial advanced sleep phase syndrome. Nature 434:640–644PubMedGoogle Scholar
  242. 242.
    Brennan KC et al (2013) Casein kinase idelta mutations in familial migraine and advanced sleep phase. Sci Transl Med 5:183ra156, 181-111Google Scholar
  243. 243.
    Oshinsky ML, Gomonchareonsiri S (2007) Episodic dural stimulation in awake rats: a model for recurrent headache. Headache 47:1026–1036PubMedCentralPubMedGoogle Scholar
  244. 244.
    Stucky NL et al (2011) Sex differences in behavior and expression of CGRP-related genes in a rodent model of chronic migraine. Headache 51:674–692PubMedCentralPubMedGoogle Scholar
  245. 245.
    Melo-Carrillo A, Lopez-Avila A (2013) A chronic animal model of migraine, induced by repeated meningeal nociception, characterized by a behavioral and pharmacological approach. Cephalalgia 33:1096–1105PubMedGoogle Scholar
  246. 246.
    Dong Z, Jiang L, Wang X, Wang X, Yu S (2011) Nociceptive behaviors were induced by electrical stimulation of the dura mater surrounding the superior sagittal sinus in conscious adult rats and reduced by morphine and rizatriptan benzoate. Brain Res 1368:151–158PubMedGoogle Scholar
  247. 247.
    Pradhan AA et al (2014) Characterization of a novel model of chronic migraine. Pain 155:269–274PubMedCentralPubMedGoogle Scholar
  248. 248.
    Pradhan AA, Smith ML, Zyuzin J, Charles A (2014) delta-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice. Br J Pharmacol 171:2375–2384PubMedGoogle Scholar
  249. 249.
    Oshinsky ML et al (2012) Spontaneous trigeminal allodynia in rats: a model of primary headache. Headache 52:1336–1349PubMedCentralPubMedGoogle Scholar
  250. 250.
    Ashkenazi A, Mushtaq A, Yang I, Oshinsky ML (2009) Ictal and interictal phonophobia in migraine-a quantitative controlled study. Cephalalgia 29:1042–1048PubMedGoogle Scholar
  251. 251.
    Romero-Reyes M et al (2013) Spontaneous behavioral responses in the orofacial region: a model of trigeminal pain in mouse. Headache 53:137–151PubMedCentralPubMedGoogle Scholar
  252. 252.
    Lipton RB et al (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63:148–158PubMedCentralPubMedGoogle Scholar
  253. 253.
    De Felice M et al (2010) Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 133:2475–2488PubMedCentralPubMedGoogle Scholar
  254. 254.
    De Felice M et al (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67:325–337PubMedGoogle Scholar
  255. 255.
    De Felice M, Porreca F (2009) Opiate-induced persistent pronociceptive trigeminal neural adaptations: potential relevance to opiate-induced medication overuse headache. Cephalalgia 29:1277–1284PubMedGoogle Scholar
  256. 256.
    De Felice M, Ossipov MH, Porreca F (2011) Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol 24:193–196PubMedGoogle Scholar
  257. 257.
    Green AL et al (2013) Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 34:594–604PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Headache Research – Section of Anaesthetics, Pain Medicine and Intensive Care, Faculty of MedicineImperial College London, Chelsea and Westminster Hospital CampusLondonUK
  2. 2.National Institute of Neurological Disorders and StrokeNational Institutes of HealthBethesdaUSA

Personalised recommendations